US2017106074A1PendingUtilityA1
Influenza Vaccine, Composition, and Methods of Use
Est. expiryJun 15, 2029(~2.9 yrs left)· nominal 20-yr term from priority
A61K 9/0043A61K 2039/55566A61K 39/099A61K 39/12A61P 31/16A61K 2039/543A61K 2039/521A61K 2039/58A61K 2039/523A61K 39/145A61K 2039/522C12N 2760/16134Y02A50/30
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of reducing lung immunopathology in a mammalian subject infected with an influenza type A virus, the method comprising the step of: prior to the subject becoming infected with the influenza type A virus, administering to the subject a sufficient amount of a live attenuated, mutated Bordetella pertussis strain to elicit an immune response which reduces influenza type A-induced lung immunopathology in the subject.
2 . The method of claim 1 , wherein the immune response elicited is sufficient to confer at least a 50% level of protection.
3 . The method of claim 1 , wherein the strain is administered intranasally.
4 . The method of claim 1 , wherein at least a first dose and a second dose of the strain are administered to the subject.
5 . The method of claim 4 , wherein the second dose is administered to the subject one to three weeks from the administration of the first dose.
6 . The method of claim 4 , wherein the live attenuated Bordetella pertussis strain comprises a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene.
7 . The method of claim 1 , wherein the live attenuated Bordetella pertussis strain comprises a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene.
8 . The method of claim 1 , wherein the live attenuated Bordetella pertussis strain is BPZE1.Join the waitlist — get patent alerts
Track US2017106074A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.